FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2291690946> ?p ?o ?g. }

• W2291690946 endingPage "3787" @default.
• W2291690946 startingPage "3782" @default.
• W2291690946 abstract "Since interferon alfa (IFN-A) became an established treatment in chronic myelogenous leukemia (CML), more patients are referred to tertiary centers in late chronic phase (ie, > 12 months after diagnosis). Trials conducted in this phase cannot be evaluated precisely unless the features that determine prognosis in late chronic-phase CML are identified. The purpose of this study is to define the prognostic determinants of late chronic-phase CML.From 1980 to 1997,257 consecutive CML patients referred in late chronic phase were studied. Their clinical characteristics at the time of referral and their association with survival were investigated. A staging model was designed.The median survival from time of referral was 43 months. Pretreatment characteristics associated with worse outcome included older age, poor performance status, splenomegaly, low albumin level, high percentage of blasts or basophils in peripheral blood (PB) or bone marrow, longer duration of chronic phase, and poor-risk group as defined by the Synthesis model. Prior exposure to IFN-A was not associated with worse outcome. By multivariate analysis, characteristics associated with shorter survival were age of 60 years or older, time from diagnosis of 3 years or greater, performance status of 1 or greater, PB basophils of 7% or greater, spleen 10 cm or greater, PB blasts 3% or greater, and albumin level less than 4 g/dL. A model that included age, duration of chronic phase, performance status, and PB basophils was generated. Patients with no, one, two, or three or greater adverse factors had median survivals of 71, 49, 26, and 19 months, respectively.A staging model for late chronic-phase CML can stratify patients in four groups with significantly different outcomes. If confirmed in independent populations, such a model could be considered in the analysis of future trials of treatment strategies in late chronic-phase CML." @default.
• W2291690946 created "2016-06-24" @default.
• W2291690946 creator A5006104041 @default.
• W2291690946 creator A5011529063 @default.
• W2291690946 creator A5015140142 @default.
• W2291690946 creator A5057701424 @default.
• W2291690946 creator A5073798523 @default.
• W2291690946 creator A5083861021 @default.
• W2291690946 creator A5090435894 @default.
• W2291690946 date "1998-12-01" @default.
• W2291690946 modified "2023-10-17" @default.
• W2291690946 title "Determinants of prognosis in late chronic-phase chronic myelogenous leukemia." @default.
• W2291690946 cites W1551203462 @default.
• W2291690946 cites W1580788756 @default.
• W2291690946 cites W1799579309 @default.
• W2291690946 cites W1893871329 @default.
• W2291690946 cites W1979300931 @default.
• W2291690946 cites W1989333836 @default.
• W2291690946 cites W1996285570 @default.
• W2291690946 cites W2019419639 @default.
• W2291690946 cites W2038952853 @default.
• W2291690946 cites W2122455557 @default.
• W2291690946 cites W2139984188 @default.
• W2291690946 cites W2292226371 @default.
• W2291690946 cites W2424919741 @default.
• W2291690946 cites W3202813470 @default.
• W2291690946 doi "https://doi.org/10.1200/jco.1998.16.12.3782" @default.
• W2291690946 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9850022" @default.
• W2291690946 hasPublicationYear "1998" @default.
• W2291690946 type Work @default.
• W2291690946 sameAs 2291690946 @default.
• W2291690946 citedByCount "23" @default.
• W2291690946 countsByYear W22916909462012 @default.
• W2291690946 countsByYear W22916909462018 @default.
• W2291690946 crossrefType "journal-article" @default.
• W2291690946 hasAuthorship W2291690946A5006104041 @default.
• W2291690946 hasAuthorship W2291690946A5011529063 @default.
• W2291690946 hasAuthorship W2291690946A5015140142 @default.
• W2291690946 hasAuthorship W2291690946A5057701424 @default.
• W2291690946 hasAuthorship W2291690946A5073798523 @default.
• W2291690946 hasAuthorship W2291690946A5083861021 @default.
• W2291690946 hasAuthorship W2291690946A5090435894 @default.
• W2291690946 hasConcept C126322002 @default.
• W2291690946 hasConcept C2776135927 @default.
• W2291690946 hasConcept C2776960273 @default.
• W2291690946 hasConcept C2778461978 @default.
• W2291690946 hasConcept C2780007613 @default.
• W2291690946 hasConcept C38180746 @default.
• W2291690946 hasConcept C512399662 @default.
• W2291690946 hasConcept C71924100 @default.
• W2291690946 hasConcept C90924648 @default.
• W2291690946 hasConceptScore W2291690946C126322002 @default.
• W2291690946 hasConceptScore W2291690946C2776135927 @default.
• W2291690946 hasConceptScore W2291690946C2776960273 @default.
• W2291690946 hasConceptScore W2291690946C2778461978 @default.
• W2291690946 hasConceptScore W2291690946C2780007613 @default.
• W2291690946 hasConceptScore W2291690946C38180746 @default.
• W2291690946 hasConceptScore W2291690946C512399662 @default.
• W2291690946 hasConceptScore W2291690946C71924100 @default.
• W2291690946 hasConceptScore W2291690946C90924648 @default.
• W2291690946 hasIssue "12" @default.
• W2291690946 hasLocation W22916909461 @default.
• W2291690946 hasLocation W22916909462 @default.
• W2291690946 hasOpenAccess W2291690946 @default.
• W2291690946 hasPrimaryLocation W22916909461 @default.
• W2291690946 hasRelatedWork W1490176706 @default.
• W2291690946 hasRelatedWork W1597450479 @default.
• W2291690946 hasRelatedWork W1966261153 @default.
• W2291690946 hasRelatedWork W1971156147 @default.
• W2291690946 hasRelatedWork W2052426387 @default.
• W2291690946 hasRelatedWork W2144075887 @default.
• W2291690946 hasRelatedWork W2371771839 @default.
• W2291690946 hasRelatedWork W2380083969 @default.
• W2291690946 hasRelatedWork W2590224211 @default.
• W2291690946 hasRelatedWork W4242089967 @default.
• W2291690946 hasVolume "16" @default.
• W2291690946 isParatext "false" @default.
• W2291690946 isRetracted "false" @default.
• W2291690946 magId "2291690946" @default.
• W2291690946 workType "article" @default.